- Home
- EXLS vs JAZZ Comparison
EXLS vs JAZZ Comparison
Compare EXLS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXLS
- JAZZ
- Stock Information
- Founded
- EXLS 1999
- JAZZ 2003
- Country
- EXLS United States
- JAZZ Ireland
- Employees
- EXLS N/A
- JAZZ N/A
- Industry
- EXLS Business Services
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- EXLS Consumer Discretionary
- JAZZ Health Care
- Exchange
- EXLS Nasdaq
- JAZZ Nasdaq
- Market Cap
- EXLS 7.1B
- JAZZ 6.7B
- IPO Year
- EXLS 2006
- JAZZ 2007
- Fundamental
- Price
- EXLS $45.22
- JAZZ $111.55
- Analyst Decision
- EXLS Strong Buy
- JAZZ Strong Buy
- Analyst Count
- EXLS 7
- JAZZ 12
- Target Price
- EXLS $49.57
- JAZZ $183.08
- AVG Volume (30 Days)
- EXLS 3.3M
- JAZZ 674.9K
- Earning Date
- EXLS 07-31-2025
- JAZZ 07-30-2025
- Dividend Yield
- EXLS N/A
- JAZZ N/A
- EPS Growth
- EXLS 21.21
- JAZZ 49.21
- EPS
- EXLS 1.32
- JAZZ 7.51
- Revenue
- EXLS $1,902,884,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- EXLS $14.18
- JAZZ $6.05
- Revenue Next Year
- EXLS $11.53
- JAZZ $4.68
- P/E Ratio
- EXLS $34.22
- JAZZ $14.87
- Revenue Growth
- EXLS 14.18
- JAZZ 5.76
- 52 Week Low
- EXLS $31.02
- JAZZ $95.49
- 52 Week High
- EXLS $52.43
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- EXLS 48.14
- JAZZ 54.01
- Support Level
- EXLS $43.73
- JAZZ $107.17
- Resistance Level
- EXLS $45.91
- JAZZ $111.51
- Average True Range (ATR)
- EXLS 1.24
- JAZZ 2.57
- MACD
- EXLS 0.06
- JAZZ 0.25
- Stochastic Oscillator
- EXLS 42.04
- JAZZ 79.17
About EXLS ExlService Holdings Inc.
ExlService Holdings Inc. is a business process management company that provides digital operations and analytical services to clients driving enterprise-scale business transformation initiatives that leverage the company's deep expertise in analytics, AI, ML, and cloud. The company offers business process outsourcing and automation services, and data-driven insights to customers across multiple industries. The company operates through four segments based on the products and services offered and markets served: Insurance, Healthcare, Emerging Business, and Analytics . The vast majority of the company's revenue is earned in the United States, and more than half of its revenue comes from Analytics segment.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.